Edition 94

Corporate

Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

JUBILANT PHARMOVA – Q1’FY23 RESULTS

The Board of Jubilant Pharmova Limited met on August 2, 2022 to approve financial results for the quarter ended June 30, 2022.

Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said:

“During the quarter, the Company reported YoY improvement in sales in Specialty Pharmaceuticals and CRDMO, which was offset by CDMO Sterile Injectables and Generics segments. In Specialty Pharmaceuticals, the Radiopharmaceuticals segment reported higher sales and profitability on account of recovery from COVID-19 impact, while Radiopharmacies business witnessed higher sales on account of recovery from pandemic and launch of new products. Our Allergy Business continues to perform strongly and witnessed healthy growth YoY. In the CDMO sterile injectables segment, revenue stood lower YoY as in Q1’FY22 the business realized higher revenue from COVID-19 related contracts as compared to this quarter. Generics segment’s performance was impacted by pricing pressure in the US market and Import Alert related challenges, which resulted in lower performance as compared to Q1’FY22.

In CRDMO, while our Drug Discovery Services segment continued to report robust growth led by higher volumes and stable pricing, the CDMO-API segment reported lower revenue as the Nanjangud plant is undergoing asset replacement and plant upgradation, which contributed to lower volumes. We are glad to share that the API demerger has become effective with April 1, 2022 as the appointed date. This demerger will enable to create synergies between CRO & CDMO businesses and help in supporting our customers for their needs from early stage of research to commercialization of active ingredients, and will provide competitive edge to this business. We would like to inform that for better understanding of performance and outlook of our various businesses, the Company has reorganised the reporting segments from Q1’FY23 onwards and the details are covered in this quarter’s investor materials.”

For more info click here

Nanjangud

A Traditional welcome to our beloved CC&MD

Mr. R Kumar, Business Head, Briefing To CC&MD

Plant Visit along with Site Leadership Team

Address By CC&MD

Temple Foundation laid by CC&MD

Honoured by Technicians

SEOY Award India 2022

Champions of a Better Tomorrow – Five pioneer social innovators are finalists of the prestigious Social Entrepreneur of the Year Award India 2022

The Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation recently announced the finalists of the 13th Social Entrepreneur of the Year Award 2022. The winner of the ‘13th Social Entrepreneur of the Year’ (SEOY) Award - India 2022 will be announced in an event on Thursday, 15 September 2022. The award ceremony will be attended by dignitaries from various fields, across the globe to celebrate and appreciate the extraordinary contribution of these passionate individuals. The SEOY award aims to honour and recognise accomplished social change leaders across a diversity of large-scale, system change models in society. The winner of the SEOY Award - India will join the world’s largest and the first inter-sectoral community of social innovators in the world affiliated with the Schwab Foundation for Social Entrepreneurship.

For more info click Here